Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age

NCT ID: NCT04280367

Last Updated: 2023-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-28

Study Completion Date

2020-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study aims to study transition toward schizophrenia in patients with learning disorders, and to compare the risk between patients with specific learning disorders, and patients with complexed learning disorders (by two types: patients with other neuro-developmental disorders including executive function disorders, and patients with anxiety).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As secondary objectives, the study aims to:

* argue the clinical predicted markers (neuropsychological) transition toward psychosis.
* test the feasibility and the acceptability of a early diagnosis for a potential applicable guidance for different referent centers of learning in French territory.
* have a better classification of patients with learning disorders in order to target a prospective primary prevention of risk of psychosis via the questionnaires (AQ of Baron-Cohen: Autism-spectrum quotient auto-questionnaire; Inventory of Beck Anxiety Inventory, auto-questionnaire for panic disorder and general anxiety; Liebowitz Social Anxiety Scale).
* improve identification of the early signs and the early emerging psychological diseases intervention management (schizophrenia).
* Psychic disability: prevent and reduce non-seeking care and accompaniment situations, and risk of rupture of care.
* permitting better care of psychosocial rehabilitation with cognitive evaluation.

This study will be conducted in Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP, in France.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Learning Disorders Executive Function Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Comparator group

Specific learning disorders group

Standardised semi-structured talk

Intervention Type DIAGNOSTIC_TEST

Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Autistic spectre disorder screening

Intervention Type DIAGNOSTIC_TEST

Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Anxiety measuring

Intervention Type DIAGNOSTIC_TEST

An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

neuro-developmental complexed group

Group of neuro-developmental complexe of learning

Standardised semi-structured talk

Intervention Type DIAGNOSTIC_TEST

Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Autistic spectre disorder screening

Intervention Type DIAGNOSTIC_TEST

Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Anxiety measuring

Intervention Type DIAGNOSTIC_TEST

An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Complexed with anxiety

Disorders in learning with anxiety

Standardised semi-structured talk

Intervention Type DIAGNOSTIC_TEST

Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Autistic spectre disorder screening

Intervention Type DIAGNOSTIC_TEST

Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Anxiety measuring

Intervention Type DIAGNOSTIC_TEST

An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardised semi-structured talk

Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Intervention Type DIAGNOSTIC_TEST

Autistic spectre disorder screening

Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Intervention Type DIAGNOSTIC_TEST

Anxiety measuring

An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients born between 1990 and 2005, have been cared by Dr Schlumberger in 2014 in the center of language and learning disorders at Raymond Poincaré hospital;
* With severe learning disorders: deficiency in school work, need at least one medical appointment and long-term rehabilitation in the center of language and learning disorders at Raymond Poincaré hospital;
* Affiliated to a social protection schema;
* Written informed consent signed.

Exclusion Criteria

* Absence of learning disorder;
* Intellectual deficiency;
* Epilepsia;
* Patients who will performed follow-up at Chartres city;
* Patients under guardianship or curatorship;
* Foreign patients under AME schema, a medical help from the state in France.
Minimum Eligible Age

15 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emilie SCHLUMBERGER, MD

Role: PRINCIPAL_INVESTIGATOR

Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP

Albane Mansoux

Role: STUDY_DIRECTOR

Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré

Garches, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A02663-54

Identifier Type: REGISTRY

Identifier Source: secondary_id

APHP191093

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.